Video
Dr. Tanya Dorff discusses CAR T-cell research in prostate cancer
Author(s):
Video Player is loading.
Tanya Dorff, MD, discusses findings from a phase 1 clinical trial (NCT03873805) which explored the use of chimeric antigen receptor (CAR) T-cell therapy in patients with prostate cancer. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.
Related Videos
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jim Hu, MD, on urinary continence recovery across RARP techniques
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Special Report: Tips for PCPs on evaluating prostate cancer risk
Special Report: Tailoring prostate cancer care for older adults
Special Report: New strategies emerge for metastatic prostate cancer
Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Related Content
